{"id":"https://openalex.org/W1978731567","doi":"https://doi.org/10.1097/00002826-200209000-00010","title":"Adjuvant Galantamine Administration Improves Negative Symptoms in a Patient With Treatment-Refractory Schizophrenia","display_name":"Adjuvant Galantamine Administration Improves Negative Symptoms in a Patient With Treatment-Refractory Schizophrenia","publication_year":2002,"publication_date":"2002-09-01","ids":{"openalex":"https://openalex.org/W1978731567","doi":"https://doi.org/10.1097/00002826-200209000-00010","mag":"1978731567","pmid":"https://pubmed.ncbi.nlm.nih.gov/12410061"},"language":"en","primary_location":{"id":"doi:10.1097/00002826-200209000-00010","doi":"https://doi.org/10.1097/00002826-200209000-00010","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00002826-200209000-00010","pdf_url":null,"source":{"id":"https://openalex.org/S3349026","display_name":"Clinical Neuropharmacology","issn_l":"0362-5664","issn":["0362-5664","1537-162X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Neuropharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048409402","display_name":"Richard B. Rosse","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1322918889","display_name":"United States Department of Veterans Affairs","ror":"https://ror.org/05rsv9s98","country_code":"US","type":"government","lineage":["https://openalex.org/I1322918889"]},{"id":"https://openalex.org/I2799886695","display_name":"Veterans Health Administration","ror":"https://ror.org/05eq41471","country_code":"US","type":"government","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695"]},{"id":"https://openalex.org/I4210154891","display_name":"Washington DC VA Medical Center","ror":"https://ror.org/050fz5z96","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210111569","https://openalex.org/I4210154891"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard B. Rosse","raw_affiliation_strings":["Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, DC 20422, USA","Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, DC 20422, USA","institution_ids":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210154891"]},{"raw_affiliation_string":"Center","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5047021203","display_name":"Stephen I. Deutsch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1322918889","display_name":"United States Department of Veterans Affairs","ror":"https://ror.org/05rsv9s98","country_code":"US","type":"government","lineage":["https://openalex.org/I1322918889"]},{"id":"https://openalex.org/I184565670","display_name":"Georgetown University","ror":"https://ror.org/05vzafd60","country_code":"US","type":"education","lineage":["https://openalex.org/I184565670"]},{"id":"https://openalex.org/I2799886695","display_name":"Veterans Health Administration","ror":"https://ror.org/05eq41471","country_code":"US","type":"government","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Stephen I. Deutsch","raw_affiliation_strings":["Mental Health Service Line, Department of Veterans Affairs Medical Center","and Department of Psychiatry, Georgetown University School of Medicine, Washington, DC, USA","Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mental Health Service Line, Department of Veterans Affairs Medical Center","institution_ids":["https://openalex.org/I1322918889","https://openalex.org/I2799886695"]},{"raw_affiliation_string":"and Department of Psychiatry, Georgetown University School of Medicine, Washington, DC, USA","institution_ids":["https://openalex.org/I184565670"]},{"raw_affiliation_string":"Center","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5047021203"],"corresponding_institution_ids":["https://openalex.org/I1322918889","https://openalex.org/I184565670","https://openalex.org/I2799886695"],"apc_list":null,"apc_paid":null,"fwci":4.9088,"has_fulltext":false,"cited_by_count":74,"citation_normalized_percentile":{"value":0.95055112,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"25","issue":"5","first_page":"272","last_page":"275"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11818","display_name":"Nicotinic Acetylcholine Receptors Study","score":0.007899999618530273,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/galantamine","display_name":"galantamine","score":1.0},{"id":"https://openalex.org/keywords/treatment-resistant-schizophrenia","display_name":"treatment-resistant schizophrenia","score":0.8410000205039978},{"id":"https://openalex.org/keywords/negative-symptoms","display_name":"negative symptoms","score":0.9850000143051147},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.8510000109672546},{"id":"https://openalex.org/keywords/acetylcholinesterase-inhibitors","display_name":"acetylcholinesterase inhibitors","score":0.9369999766349792},{"id":"https://openalex.org/keywords/nicotinic-acetylcholine-receptors","display_name":"nicotinic acetylcholine receptors","score":0.8309999704360962},{"id":"https://openalex.org/keywords/positive-allosteric-modulation","display_name":"positive allosteric modulation","score":0.9440000057220459},{"id":"https://openalex.org/keywords/scale-for-the-assessment-of-negative-symptoms","display_name":"Scale for the Assessment of Negative Symptoms","score":0.8629999756813049},{"id":"https://openalex.org/keywords/cognitive-impairment","display_name":"cognitive impairment","score":0.6589999794960022},{"id":"https://openalex.org/keywords/mood-disturbance","display_name":"mood disturbance","score":0.746999979019165},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.7820000052452087}],"concepts":[{"id":"https://openalex.org/C2779056891","wikidata":"https://www.wikidata.org/wiki/Q412690","display_name":"Galantamine","level":5,"score":0.976495623588562},{"id":"https://openalex.org/C2778816929","wikidata":"https://www.wikidata.org/wiki/Q22676679","display_name":"Acetylcholinesterase","level":3,"score":0.6722003221511841},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.5260602831840515},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5136789679527283},{"id":"https://openalex.org/C31896038","wikidata":"https://www.wikidata.org/wiki/Q415635","display_name":"Cholinesterase","level":2,"score":0.4880181849002838},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4808114767074585},{"id":"https://openalex.org/C2780442968","wikidata":"https://www.wikidata.org/wiki/Q7429722","display_name":"Scale for the Assessment of Negative Symptoms","level":4,"score":0.4750157296657562},{"id":"https://openalex.org/C22885893","wikidata":"https://www.wikidata.org/wiki/Q4862743","display_name":"Cholinergic","level":2,"score":0.47466352581977844},{"id":"https://openalex.org/C2777544248","wikidata":"https://www.wikidata.org/wiki/Q2592323","display_name":"Acetylcholinesterase inhibitor","level":4,"score":0.46300745010375977},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.43352073431015015},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3759845495223999},{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.3725665211677551},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.36937040090560913},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.2744043469429016},{"id":"https://openalex.org/C2780904820","wikidata":"https://www.wikidata.org/wiki/Q415081","display_name":"Donepezil","level":4,"score":0.19666582345962524},{"id":"https://openalex.org/C2778528637","wikidata":"https://www.wikidata.org/wiki/Q4967025","display_name":"Brief Psychiatric Rating Scale","level":3,"score":0.1830241084098816},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.1698683798313141},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.16648688912391663},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.07259160280227661},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003024","descriptor_name":"Clozapine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003024","descriptor_name":"Clozapine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005702","descriptor_name":"Galantamine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005702","descriptor_name":"Galantamine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D005702","descriptor_name":"Galantamine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011978","descriptor_name":"Receptors, Nicotinic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00002826-200209000-00010","doi":"https://doi.org/10.1097/00002826-200209000-00010","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00002826-200209000-00010","pdf_url":null,"source":{"id":"https://openalex.org/S3349026","display_name":"Clinical Neuropharmacology","issn_l":"0362-5664","issn":["0362-5664","1537-162X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Neuropharmacology","raw_type":"journal-article"},{"id":"pmid:12410061","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12410061","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical neuropharmacology","raw_type":"Case Reports"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W1532317254","https://openalex.org/W1643478577","https://openalex.org/W1991313827","https://openalex.org/W2027977900","https://openalex.org/W2036999109","https://openalex.org/W2041495183","https://openalex.org/W2072486526","https://openalex.org/W2089868642","https://openalex.org/W2090019512","https://openalex.org/W2122692162"],"related_works":["https://openalex.org/W2011852864","https://openalex.org/W3191929620","https://openalex.org/W2081210477","https://openalex.org/W2004286836","https://openalex.org/W2151012619","https://openalex.org/W2155797616","https://openalex.org/W2165321423","https://openalex.org/W2052647387","https://openalex.org/W2938166470","https://openalex.org/W1982834811"],"abstract_inverted_index":{"Because":[0],"of":[1,4,22,52,59,70,91,103,119,127,138,152,160,171,188,214,216],"the":[2,19,68,80,100,116,147,150,168,212,217,230],"demonstration":[3],"a":[5,29,55,64,89,132,157],"selective":[6],"alpha":[7],"nicotinic":[8,60,221],"receptor":[9],"abnormality":[10],"in":[11,28,143,179,233,237],"patients":[12,71],"with":[13,72],"schizophrenia,":[14],"galantamine":[15,161],"was":[16,86,97,108,131],"added":[17],"to":[18,74,110,167,175,229],"stable":[20],"regimen":[21],"atypical":[23],"and":[24,34,37,45,54,106,134,190,195],"other":[25,202],"antipsychotic":[26],"medications":[27],"43-year-old":[30],"man":[31],"manifesting":[32],"severe":[33],"persistent":[35],"positive":[36,56,207,241],"negative":[38,139,163,234],"symptoms,":[39,140],"as":[40,42,141],"well":[41],"mood":[43],"disturbance":[44],"cognitive":[46],"dysfunction.":[47],"Galantamine":[48,84,198],"is":[49,199],"an":[50,185],"inhibitor":[51],"acetylcholinesterase":[53,181,203],"allosteric":[57,208],"modulator":[58],"cholinergic":[61],"receptors":[62],"(with":[63],"FDA-approved":[65],"indication":[66],"for":[67,99,149],"treatment":[69],"mild":[73],"moderate":[75],"Alzheimer":[76],"disease":[77],"(AD)":[78],"under":[79],"trade":[81],"name":[82],"Reminyl).":[83],"HBr":[85],"initiated":[87],"at":[88,220],"dose":[90],"4":[92],"mg":[93,112],"po":[94,113],"BID,":[95],"which":[96],"maintained":[98],"first":[101],"week":[102,126],"adjuvant":[104],"therapy,":[105],"eventually":[107],"increased":[109],"12":[111],"BID":[114],"during":[115,245],"final":[117],"weeks":[118],"his":[120],"2-month":[121,247],"trial.":[122],"Remarkably,":[123],"within":[124,156],"1":[125],"its":[128,206],"initiation,":[129],"there":[130],"dramatic":[133],"clinically":[135],"significant":[136],"decrease":[137],"reflected":[142],"formal":[144],"ratings":[145],"on":[146],"Scale":[148],"Assessment":[151],"Negative":[153],"Symptoms.":[154],"Moreover,":[155],"few":[158],"days":[159],"discontinuation,":[162],"symptoms":[164,235,242],"worsened,":[165],"returning":[166],"baseline":[169],"level":[170],"severity.":[172],"In":[173],"addition":[174],"targeting":[176],"memory":[177],"dysfunction":[178],"AD,":[180],"inhibitors":[182,204],"may":[183,226],"have":[184,227],"expanded":[186],"range":[187],"targets":[189],"clinical":[191],"indications,":[192],"including":[193],"behavioral":[194],"psychotic":[196],"symptoms.":[197],"distinguished":[200],"from":[201],"by":[205],"modulatory":[209],"properties,":[210],"improving":[211],"efficiency":[213],"transduction":[215],"acetylcholine":[218],"signal":[219],"receptors.":[222],"This":[223],"latter":[224],"property":[225],"contributed":[228],"observed":[231,236],"improvement":[232],"this":[238,246],"patient.":[239],"Importantly,":[240],"were":[243],"unchanged":[244],"trial.(7)":[248]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}